By the Banger Labs Research Team · Updated June 2026
What is FOXO4-DRI?
FOXO4-DRI is a synthetic peptide first described by Baar et al. (Cell, 2017) and engineered in a “D-retro-inverso” configuration, meaning it is built from D-amino acids in reverse sequence to confer protease resistance while preserving binding geometry. It is derived from the p53-binding region of the FOXO4 transcription factor and is paired with a cationic cell-permeability segment. It is handled strictly as a laboratory research compound.
How FOXO4-DRI is studied
In published preclinical and in vitro research models, senescent cells are reported to upregulate FOXO4, which sequesters p53 and limits apoptotic signaling. FOXO4-DRI is studied as a competitive disruptor of the FOXO4-p53 interaction; recent structural work (Nature Communications, 2025) characterizes its binding to the disordered p53 transactivation domain (p53TAD2). In these research models, disruption of this interaction has been associated with p53 nuclear exclusion and activation of pro-apoptotic signaling (e.g., BAX) in senescent cells. These are mechanistic research observations only and do not imply any human effect.
Research areas
- Studied in cellular-senescence research as a tool to probe the FOXO4-p53 protein-protein interaction
- Investigated in in vitro models of senescent-cell biology (e.g., expanded human chondrocytes)
- Examined in preclinical aging/healthspan research models (Baar et al., 2017)
- Used in structural-biology research characterizing binding to the disordered p53 transactivation domain (p53TAD2)
- Explored in preclinical research models of endothelial and tissue-specific cellular senescence
These describe laboratory/preclinical research only. No therapeutic, medical, or efficacy claims are made.
FOXO4-DRI specifications
Handling & quality
FOXO4-DRI is held to a ≥ 99% HPLC purity standard with a Certificate of Analysis available per batch. Reconstitute with bacteriostatic water and store refrigerated; handle strictly for research. See reconstitution & storage.
Frequently asked questions
What is FOXO4-DRI?
FOXO4-DRI is a synthetic peptide first described by Baar et al. (Cell, 2017) and engineered in a “D-retro-inverso” configuration, meaning it is built from D-amino acids in reverse sequence to confer protease resistance while preserving binding geometry. It is derived from the p53-binding region of the FOXO4 transcription factor and is paired with a cationic cell-permeability segment. It is handled strictly as a laboratory research compound.
Is FOXO4-DRI research use only?
Yes. FOXO4-DRI is supplied strictly for laboratory research — not for human or veterinary use, and not as a drug, food, or supplement.
Does Banger Labs provide a COA for FOXO4-DRI?
Yes — a Certificate of Analysis (HPLC purity + mass-spec identity) is available per batch on request. See the COA Library.
References
- Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes — Frontiers in Bioengineering and Biotechnology
- The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI — Nature Communications
- FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway — PMC / NCBI
Sources are provided for scientific reference and describe laboratory/preclinical research; they do not constitute medical advice or efficacy claims.
Shop FOXO4-DRI & related research peptides
By the Banger Labs Research Team. For research use only. Not for human or veterinary use. Not a drug, food, or cosmetic. Educational information, not medical advice.